$242 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 69 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ATHA | New | ATHIRA PHARMA INC | $26,964,000 | – | 10,000 | +100.0% | 11.16% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $5,354,000 | – | 105,368 | +100.0% | 2.22% | – |
| NGM | New | NGM BIOPHARMACEUTICALS INC | $3,058,000 | – | 200,494 | +100.0% | 1.26% | – |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $1,920,000 | – | 20,482 | +100.0% | 0.80% | – |
| CDXS | New | CODEXIS INC | $1,670,000 | – | 81,000 | +100.0% | 0.69% | – |
| FMTX | New | FORMA THERAPEUTICS HLDGS INC | $1,625,000 | – | 174,768 | +100.0% | 0.67% | – |
| ISEE | New | IVERIC BIO INCput | $1,592,000 | – | 94,600 | +100.0% | 0.66% | – |
| IMGN | New | IMMUNOGEN INCcall | $1,428,000 | – | 300,000 | +100.0% | 0.59% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $1,428,000 | – | 25,000 | +100.0% | 0.59% | – |
| IMUX | New | IMMUNIC INC | $774,000 | – | 68,475 | +100.0% | 0.32% | – |
| New | ELIEM THERAPEUTICS INC | $741,000 | – | 88,279 | +100.0% | 0.31% | – | |
| APTX | New | APTINYX INCput | $458,000 | – | 201,600 | +100.0% | 0.19% | – |
| New | AMYLYX PHARMACEUTICALS INC | $386,000 | – | 30,000 | +100.0% | 0.16% | – | |
| BCRX | New | BIOCRYST PHARMACEUTICALS INC | $197,000 | – | 102,425 | +100.0% | 0.08% | – |
| ALGS | New | ALIGOS THERAPEUTICS INC | $23,000 | – | 10,659 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.